Optimization of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines to generate a highly selective PI3Kδ inhibitor

Add time:07/11/2019    Source:sciencedirect.com

Chemical optimization of the 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine (THPP) scaffold was conducted with a focus on cellular potency while maintaining high selectivity against PI3K isoforms. Compound 11f was identified as a potent, highly selective and orally available PI3Kδ inhibitor. In addition, 11f exhibited efficacy in an in vivo antibody production model. The desirable drug-like properties and in vivo efficacy of 11f suggest its potential as a drug candidate for the treatment of autoimmune diseases and leukocyte malignancies.

We also recommend Trading Suppliers and Manufacturers of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-ol hydrochloride (cas 1956321-99-5). Pls Click Website Link as below: cas 1956321-99-5 suppliers

Prev:Ether-free polymeric anion exchange materials with extremely low vanadium ion permeability and outstanding cell performance for vanadium redox flow battery (VRFB) application
Next:Discovery of tetrahydropyrido[4,3-d]pyrimidine derivatives for the treatment of neuropathic pain)